Drug Trial Radar · NCT00796653
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
Last checked: Nov 19, 2026Latest source record: Jun 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
937
Actual
Start
Jan 2009
Primary completion
Dec 2010
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI 1744)Drug
Comparison of low and high doses on efficacy and safety in COPD patients
Olodaterol (BI 1744)Drug
Comparison of low and high doses on efficacy and safety in COPD patients
FormoterolDrug
Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
PlaceboDrug
Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 WeeksTime frame: 1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24
- Trough FEV1 Response at Week 24Time frame: 1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 24.
- Mahler Transitional Dyspnea Index Focal Score at 24 WeeksTime frame: Baseline, Week 24
- Mahler Transitional Dyspnea Index Focal Score at 24 Weeks for Combined AnalysisTime frame: Baseline, Week 24
Locations
98 sites in 20 countries. Site status is shown where the registry gives one.
1222.14.5004 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1222.14.5003 Boehringer Ingelheim Investigational Site
Mar del Plata, Argentina
1222.14.5001 Boehringer Ingelheim Investigational Site
Mendoza, Argentina
1222.14.5002 Boehringer Ingelheim Investigational Site
Quilmes, Argentina
1222.14.5005 Boehringer Ingelheim Investigational Site
San Juan Bautista, Argentina
1222.14.5106 Boehringer Ingelheim Investigational Site
Florianópolis, Brazil
1222.14.5101 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1222.14.5103 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1222.14.5104 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1222.14.5102 Boehringer Ingelheim Investigational Site
Recife, Brazil
1222.14.5105 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1222.14.4005 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1222.14.4002 Boehringer Ingelheim Investigational Site
Kelowna, British Columbia, Canada
1222.14.4004 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1222.14.4009 Boehringer Ingelheim Investigational Site
Moncton, New Brunswick, Canada
1222.14.4010 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador, Canada
1222.14.4008 Boehringer Ingelheim Investigational Site
Grimsby, Ontario, Canada
1222.14.4014 Boehringer Ingelheim Investigational Site
Mississauga, Ontario, Canada
1222.14.4007 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1222.14.4013 Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
1222.14.4001 Boehringer Ingelheim Investigational Site
Scarborough Village, Ontario, Canada
1222.14.4012 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1222.14.4006 Boehringer Ingelheim Investigational Site
Québec, Quebec, Canada
1222.14.4015 Boehringer Ingelheim Investigational Site
Sherbrooke, Quebec, Canada
1222.14.4011 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
1222.14.6004 Boehringer Ingelheim Investigational Site
Brno, Czechia
1222.14.6003 Boehringer Ingelheim Investigational Site
Hradec Králové, Czechia
1222.14.6002 Boehringer Ingelheim Investigational Site
Kyjov, Czechia
1222.14.6001 Boehringer Ingelheim Investigational Site
Znojmo, Czechia
1222.14.4602 Boehringer Ingelheim Investigational Site
Elsinore, Denmark
1222.14.4601 Boehringer Ingelheim Investigational Site
Hillerød, Denmark
1222.14.4603 Boehringer Ingelheim Investigational Site
Roskilde, Denmark
1222.14.4702 Boehringer Ingelheim Investigational Site
Espoo, Finland
1222.14.4701 Boehringer Ingelheim Investigational Site
HUS, Finland
1222.14.4703 Boehringer Ingelheim Investigational Site
Lohja, Finland
1222.14.4106 Boehringer Ingelheim Investigational Site
Aschaffenburg, Germany
1222.14.4112 Boehringer Ingelheim Investigational Site
Berlin, Germany
1222.14.4103 Boehringer Ingelheim Investigational Site
Frankfurt, Germany
1222.14.4110 Boehringer Ingelheim Investigational Site
Frankfurt, Germany
1222.14.4108 Boehringer Ingelheim Investigational Site
Gelnhausen, Germany
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.